FTX-101(Find Therapeutics)

This is a Phase 1, first-in-human (FIH), single-center, randomized, double-blind, placebo-controlled study in healthy male subjects. The study will include the following 2 parts:
* Part A: Single Ascending Dose (SAD) with a nested absolute bioavailability cohort in healthy male subjects
* Part B: Multiple Ascending Dose (MAD) in healthy male subjects